Women's Health · ContraceptiveRegulatory Approvalregulatorymid-term

FDA Grants AP Status for Desogestrel and Ethinyl Estradiol ANDA219670

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Annora Pharma6 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/12/2026, 6:30:30 AM

Assessment confidence: 61% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's grant of Abbreviated Approval status for Annora Pharma's ANDA219670 signifies a notable advancement in the contraceptive market, potentially altering competitive dynamics. Pharma strategy teams should closely observe this development to understand its implications on market positioning and competitive strategies. Regulatory context from FDA (FDA AP — DESOGESTREL AND ETHINYL ESTRADIOL (ORIG)) supports the near-term read. Assessment grounded in 22 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the competitive landscape for contraceptives and consider strategic positioning against Annora's offering. The strongest clinical anchor is VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women (ClinicalTrials.gov), moderate corpus alignment. In Women's Health · Contraceptive, 8 regulatory and 1 competitive items passed relevance filtering for Annora Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for TRUTAKNA (BLA761486) by Vera Therapeutics (Humanexa Signals) — moderate corpus alignment. This approval may enhance Annora Pharma's position in the contraceptive market, potentially impacting competitors with similar products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DESOGESTREL AND ETHINYL ESTRADIOL (ORIG) (FDA). Entity match (annora pharma); Regulatory pathway relevance (nda).

Key Risks

Elevated medium regulatory exposure for Annora Pharma could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Disparities in Emergency Contraceptive Metabolism Dictate Efficacy) could weigh on Annora Pharma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Annora Pharma's new approval could capture market share from existing contraceptive products, impacting revenue streams for competitors. Strategic responses may be necessary to maintain competitive positioning.
Upside for Annora Pharma may improve if Health Benefits of Dance Exercise (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the competitive landscape for contraceptives and consider strategic positioning against Annora's offering.

What Would Change This Assessment

This becomes more urgent if Monitor for market entry timelines and any potential challenges from competitors.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DESOGESTREL AND ETHINYL ESTRADIOL (ORIG)
FDAhigh relevance
Entity match (annora pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ESTRADIOL (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ESTRADIOL AND NORETHINDRONE ACETATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ESTRADIOL (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — INTROVALE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Disparities in Emergency Contraceptive Metabolism Dictate Efficacy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Shaping Community-based Pathway to Improve TB Surveillance Among African and Hindustan Immigrants Experiencing Vulnerabilities
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Health Benefits of Dance Exercise
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Reducing Disparities in Behavioral Health Treatment for Children in Primary Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Trial to Investigate the Efficacy and Safety of Plant-derived Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for TRUTAKNA (BLA761486) by Vera Therapeutics
Humanexa Signalsmedium relevance
Moderate corpus alignment

Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Real-world effectiveness of HPV vaccination against high-risk type HPV DNA positivity among adult women aged 18 - 45years in China: A matched test-negative design study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
' they just take one pill, so it is easy to use, more convenient ': South African health care provider perspectives on Dual Prevention Pill.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Annora Pharma
Desogestrel

Commercial impact

medium

Annora Pharma's new approval could capture market share from existing contraceptive products, impacting revenue streams for competitors. Strategic responses may be necessary to maintain competitive positioning.

Regulatory impact

medium

The approval indicates a successful regulatory pathway for Annora Pharma, which may prompt other companies to reassess their product development timelines and regulatory strategies in the contraceptive space.

What to watch

Monitor for market entry timelines and any potential challenges from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.